Please login to the form below
tafamidis
This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.
Latest news
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
Vyndaqel (tafamidis meglumine) has been approved since 2011 for stage 1 polyneuropathy associated with ATTR, but the cardiomyopathy approval significantly extends the eligible patient population for the drug, already growing quickly
-
Vyndaqel a bright spot as Pfizer comes under pressure
The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier
-
Pfizer buys dwarfism drug company Therachon for $810m
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)
-
Speedy approval for Pfizer's Onpattro rival
Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Pfizer filed the drug in two oral formulations, one known as Vyndaqel
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Associate Account Director
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
-
Publications Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- bluebird bio aiming to separate business units by year-end
- InSite Events™ selected as an honorable mention in Fast Company’s 2021 World Changing Ideas Awards
- THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
- Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants
- FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
- US backs proposal to waive IP protection for COVID-19 vaccines
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Why female mentorship is so powerful in pharma
- CanSinoBIO considers booster jab for COVID-19 vaccine
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Moderna COVID-19 vaccine shortfall could affect UK supply
- NICE sets out plans for ‘ambitious’ five-year strategy
- Working in true partnership in a time of change
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
